SEE THE DIFFERENCE
Xiidra works differently from cyclosporine to address dry eye inflammation1-5*
A Key Driver: 
Inflammation
Up to 65% of patients with dry eye may have clinically significant ocular surface inflammation7
Rapid and
lasting relief
Xiidra can start to deliver symptom relief as early as 2 weeks1‡
ICAM-1, intercellular adhesion molecule 1; LFA-1, lymphocyte function-associated antigen 1.
The exact mechanisms of action of Xiidra and cyclosporine in dry eye disease are not known.
*There are no head-to-head studies of Xiidra and cyclosporine.
†Based on in vitro data.1
‡Xiidra significantly reduced symptoms of eye dryness at 2 weeks (based on Eye Dryness Score compared to vehicle) in 2 of 4 studies, with improvements observed at 6 and 12 weeks in all 4 studies.1
Indication and important safety information
Indication
Xiidra® (lifitegrast ophthalmic solution) 5% is indicated for the treatment of signs and symptoms of dry eye disease (DED).
Important Safety Information
- Xiidra is contraindicated in patients with known hypersensitivity to lifitegrast or to any of the other ingredients.
- In clinical trials, the most common adverse reactions reported in 5-25% of patients were instillation site irritation, dysgeusia and reduced visual acuity. Other adverse reactions reported in 1% to 5% of the patients were blurred vision, conjunctival hyperemia, eye irritation, headache, increased lacrimation, eye discharge, eye discomfort, eye pruritus and sinusitis.
- To avoid the potential for eye injury or contamination of the solution, patients should not touch the tip of the single-use container to their eye or to any surface.
- Contact lenses should be removed prior to the administration of Xiidra and may be reinserted 15 minutes following administration.
- Safety and efficacy in pediatric patients below the age of 17 years have not been established.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
Click here for full Prescribing Information for Xiidra.
References
- Xiidra. Prescribing information. Bausch & Lomb Inc.
- Restasis. Prescribing information. Allergan; 2017.
- Vevye. Prescribing information. Harrow Eye, LLC; 2023.
- Cequa. Prescribing information. Sun Pharmaceutical Industries Limited; 2022.
- Donnenfeld ED, Perry HD, Nattis AS, Rosenberg ED. Lifitegrast for the treatment of dry eye disease in adults. Expert Opin Pharmacother. 2017;18(14):1517-1524. doi:10.1080/14656566.2017.1372748
- Bron AJ, de Paiva CS, Chauhan SK, et al. TFOS DEWS II pathophysiology report. Ocul Surf. 2017;15(3):438-510.
- Data on file. NPR.0002.USA.24, 2024. Bausch & Lomb Inc.
Indication and important safety information
Indication
Xiidra® (lifitegrast ophthalmic solution) 5% is indicated for the treatment of signs and symptoms of dry eye disease (DED).
Important Safety Information
- Xiidra is contraindicated in patients with known hypersensitivity to lifitegrast or to any of the other ingredients.
- In clinical trials, the most common adverse reactions reported in 5-25% of patients were instillation site irritation, dysgeusia and reduced